German Merck Aims To Lift Its UK R&D Efforts, Despite Brexit Uncertainty

Germany's Merck Group plans to bolster its biopharma R&D activities in Britain - despite Brexit - on grounds the UK is too key and dynamic a player in the life sciences sphere not to - and because the conglomerate needs to be there to help ensure its evolution into a top oncology and immuno-oncology innovator.